Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)
- Authors:
- Paulina Kozakiewicz
- Ludmiła Grzybowska‑Szatkowska
-
Affiliations: Department of Oncology, Medical University of Lublin, 20‑90 Lublin, Poland - Published online on: March 20, 2018 https://doi.org/10.3892/ol.2018.8300
- Pages: 7497-7505
This article is mentioned in:
Abstract
|
Vigneswaran N and Williams MD: Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 26:123–141. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Macmillan Cancer Support: Types of head and neck cancer. https://www.macmillan.org.uk/information-and-support/head-and-neck-cancers/understanding-cancer/types-head-neck-cancer.htmlFeb. 2016 | |
|
Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, et al: Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 18:541–550. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fung C and Grandis JR: Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 15:355–373. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, et al: NCCN Guidelines insights: Head and neck cancers, version 2.2017. J Natl Compr Canc Netw. 15:761–770. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Brierley JD, Gospodarowicz MK and Wittekind CH: TNM Classification of Malignant Tumours Eighth Edition. Chichester, West Sussex, UK; Hoboken, NJ: John Wiley & Sons, Inc.; 2017 | |
|
Pignon JP, le Maitre A, Maillard E and Bourhis J: MACH-NC Collaborative Group: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 92:4–14. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Suh Y, Amelio I, Urbano Guerrero T and Tavassoli M: Clinical update on cancer: Molecular oncology of head and neck cancer. Cell Death Dis. 5:e10182014. View Article : Google Scholar : PubMed/NCBI | |
|
Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M and Lardon F: Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: Focus on potential molecular mechanisms of drug resistance. Oncologist. 18:850–864. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
National Cancer Institute: NCI Dictionary of Cancer Terms: Definition of targeted therapy. https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=270742Feb. 2016 | |
|
Goerner M, Seiwert TY and Sudhoff H: Molecular targeted therapies in head and neck cancer-An update of recent developments. Head Neck Oncol. 2:82010. View Article : Google Scholar : PubMed/NCBI | |
|
Song J, Chen C and Raben D: Emerging role of EGFR-Targeted therapies and radiation in head and neck cancer. Oncology (Williston Park). 18(1757–1767): 1771–1772, 1777. 2004. | |
|
Lurje G and Lenz HJ: EGFR signaling and drug discovery. Oncology. 77:400–410. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Schwab M: Broder histological classificationEncyclopedia of Cancer. Berlin Heidelberg: Springer; 2011, View Article : Google Scholar : PubMed/NCBI | |
|
Alterio D, Marvaso G, Maffini F, Gandini S, Chiocca S, Ferrari A, Preda L, Rocca MC, Lepanto D, Fodor C, et al: Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: Proposal of a new approach behind the EGFR overexpression. Med Oncol. 34:1072017. View Article : Google Scholar : PubMed/NCBI | |
|
Keren S, Shoude Z, Lu Z and Beibei Y: Role of EGFR as a prognostic factor for survival in head and neck cancer: A meta-analysis. Tumour Biol. 35:2285–2295. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Markovic A and Chung CH: Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 12:1149–1159. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Obradović J, Djordjević N, Tošic N, Mrdjanović J, Stanković B, Stanić J, Zarić B, Perin B, Pavlović S and Jurišić V: Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: A preliminary study. Tumour Biol. 37:10479–10486. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Matta A and Ralhan R: Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol. 1:62009. View Article : Google Scholar : PubMed/NCBI | |
|
Huang SM and Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 6:2166–2174. 2000.PubMed/NCBI | |
|
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, et al: Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 32:2940–2950. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM and St Guily Lacau J: Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. Int J Cancer. 136:1494–1503. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, Baert F, Van Laethem JL, Speleman F, Pauwels P and Peeters M: Epidermal growth factor receptor and K-ras status in two cohorts of squamous cell carcinomas. BMC Cancer. 10:1892010. View Article : Google Scholar : PubMed/NCBI | |
|
Burtness B, Goldwasser MA, Flood W, Mattar B and Forastiere AA: Eastern Cooperative Oncology Group: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study. J Clin Oncol. 23:8646–8654. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11:21–28. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q and Gutkind JS: mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst. 106:pii:dju2152014. View Article : Google Scholar | |
|
Boeckx C, de Beeck Op K, Wouters A, Deschoolmeester V, Limame R, Zwaenepoel K, Specenier P, Pauwels P, Vermorken JB, Peeters M, et al: Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins. Cancer Lett. 354:365–377. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, et al: HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 15:3740–3750. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, et al: Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial. Lancet Oncol. 14:697–710. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eriksen JG, Maare C, Johansen J, Primdahl H, Evensen J, Kristensen CA, Andersen LJ and Overgaard J: DAHANCA19: A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas. ESTRO 33 Congress Report. 112014. | |
|
Sundaram S, Venkatanarayan B, Sridharan N and Poojar K: Nimotuzumab with induction chemotherapy and chemo-radiation in patients with advanced head and neck cancer. J Cancer Ther. 6:146–152. 2015. View Article : Google Scholar | |
|
ClinicalTrials.gov, . NCT02012062 phase III study of neoadjuvant TPF chemotherapy followed by radiotherapy and concurrent nimotuzumab or cisplatin for locoregionally advanced nasopharyngeal carcinoma (NPC). https://clinicaltrials.gov/ct2/show/NCT02012062Sept. 2015 | |
|
Chapman CH, Saba NF and Yom SS: Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: Still lost in translation? Ann Transl Med. 4:802016.PubMed/NCBI | |
|
Kit OI, Vodolazhsky DI, Timoshkina NN, Vladimirova LY, Turkin IN, Kutsyn KA, Enin YS, Panina SB and Jurisic V: EGFR mutations and tumor metastases in patients with nonsmall cell lung cancer in the South οf Russia. J BUON. 22:1410–1415. 2017.PubMed/NCBI | |
|
Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G and Zwierzina H: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer. 42:109–111. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, et al: Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol. 31:1415–1421. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fumagalli I, Dugue D, Bibault JE, Clémenson C, Vozenin MC, Mondini M and Deutsch E: Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. Onco Targets Ther. 8:335–345. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza FH, Fayette J, Mehanna H, El-Hariry I, Compton N, et al: Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer. 49:1609–1618. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Weiss JM, Bagley S, Hwang WT, Bauml J, Olson JG, Cohen RB, Hayes DN and Langer C: Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer. 122:2350–2355. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Modjtahedi H, Cho BC, Michel MC and Solca F: A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol. 387:505–521. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E and Cohen EE: A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 25:1813–1820. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Burtness B, Bourhis JP, Vermorken JB, Harrington KJ and Cohen EE: Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: Study protocol for a randomized controlled trial. Trials. 15:4692014. View Article : Google Scholar : PubMed/NCBI | |
|
Razak Abdul AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan PF, Chen EX, et al: A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol. 24:761–769. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW and Villaret DB: Postoperative irradiation for squamous cell carcinoma of the oral cavity: 35 year experience. Head Neck. 26:984–994. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Minchenko A, Bauer T, Salceda S and Caro J: Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest. 3:374–379. 1994. | |
|
Kyzas PA, Cunha IW and Ioannidis JP: Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis. Clin Cancer Res. 11:1434–1440. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z and Xu XH: Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma. Saudi Med J. 36:659–664. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vokes EE, Cohen EEW, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, Kozloff MF, Dancey J and Dekker A: A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol. 23 Suppl 16:S55042005. View Article : Google Scholar | |
|
Burtness B: Commentary Bevacizumab and erlotinib with chemoradiation for head and neck cancer. Cancer J. 17:273–275. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, et al: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I/II study. Lancet Oncol. 3:247–257. 2009. View Article : Google Scholar | |
|
Feinstein T, Raez L, Rajasenan K, Gibson MK, Savvides P, Karamouzis MV, Garg N, Johnson R, Branstetter BF and Argiris AE: Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): Updated results of a Phase II trial. J Clin Oncol. 26 15 Suppl:S60692008. View Article : Google Scholar | |
|
Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, et al: Cetuximab and bevacizumab: Preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 24:220–225. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fury MG, Lee NY, Sherman E, Lisa D, Kelly K, Lipson B, Carlson D, Stambuk H, Haque S, Shen R, et al: A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer. 15:5008–5014. 2012. View Article : Google Scholar | |
|
ClinicalTrials.gov, . NCT00968435 Bevacizumab, Cetuximab, and cisplatin with IMRT (Intensity-Modulated Radiation Therapy) for patients with stage III/IV head and neck squamous cell carcinoma. https://clinicaltrials.gov/ct2/show/NCT00968435/Jun. 2016 | |
|
Zhang Y, Xue D, Wang X, Lu M, Gao B and Qiao X: Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways. Mol Med Rep. 9:83–90. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yadav A, Kumar B, Teknos TN and Kumar P: Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther. 10:1241–1251. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Möckelmann N, Rieckmann T, Busch CJ, Becker B, Gleissner L, Hoffer K, Omniczynski M, Steinmeister L, Laban S, Grénman R, et al: Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. Oncotarget. 7:23542–23551. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Laban S, Steinmeister L, Gleissner L, Grob TJ, Grénman R, Petersen C, Gal A, Knecht R, Dikomey E and Kriegs M: Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. Radiother Oncol. 109:286–292. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC and Milano G: Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol. 20:1703–1707. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, et al: Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006–01. J Clin Oncol. 28:21–28. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, et al: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 25:4270–4277. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, et al: Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 38:439–447. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS and Mirshahidi S: Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol. 50:19–26. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter UD: Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Oncol Rep. 38:1877–1885. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, et al: A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Invest New Drugs. 33:1248–1256. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu HW, de Necochea-Campion R, Williams V, Duerksen-Hughes PJ, Simental AA Jr, Ferris RL, Chen CS and Mirshahidi S: Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells. Oral Oncol. 50:662–669. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kramer B, Hock C, Birk R, Sauter A, Stuck BA, Hörmann K, Schultz JD and Aderhold C: Targeted therapies in HPV-positive and -negative HNSCC-Alteration of EGFR and VEGFR-2 expression in vitro. Anticancer Res. 36:2799–2807. 2016.PubMed/NCBI | |
|
LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist Updat. 11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lionello M, Blandamura S, Loreggian L, Ottaviano G, Giacomelli L, Marchese-Ragona R, Velardita C, Staffieri A and Marioni G: High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: A pilot study. J Oral Pathol Med. 41:136–140. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zaytseva YY, Valentino JD, Gulhati P and Evers BM: mTOR inhibitors in cancer therapy. Cancer Lett. 319:1–7. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schedel F, Pries R, Thode B, Wollmann B, Wulff S, Jocham D, Wollenberg B and Kausch I: mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep. 25:763–768. 2011.PubMed/NCBI | |
|
Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A and Caldito G: Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 67:2160–2168. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, et al: A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 49:461–467. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Niehr F, Weichert W, Stenzinger A, Budach V and Tinhofer I: CCI-779 (Temsirolimus) exhibits increased antitumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. J Transl Med. 13:1062015. View Article : Google Scholar : PubMed/NCBI | |
|
Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, et al: Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors. Eur J Cancer. 81:81–89. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li SH, Lin WC, Huang TL, Chen CH, Chiu TJ, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, et al: Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. Head Neck. 38 Suppl 1:E844–E852. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
ClinicalTrials.gov, . NCT01016769 temsirolimus + weekly paclitaxel + carboplatin for recurrent or metastatic head and neck squamous cell cancer (HNSCC). https://clinicaltrials.gov/ct2/show/NCT01016769Feb. 2016 | |
|
ClinicalTrials.gov, . Everolimus versus placebo in head and neck cancer. https://clinicaltrials.gov/ct2/show/NCT0111105820–Feb. 2016 | |
|
Grzywnowicz M and Giannopoulos K: The role of receptor programmed death-1 and its ligands in immune system and tumors. Acta Haematol Pol. 43:132–145. 2012. View Article : Google Scholar | |
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2369:134–144. 2013. View Article : Google Scholar | |
|
Mehra R, Seiwert TY, Mahipal A, Weiss J, Berger R, Eder JP, Burtness B, Tahara M, Keam B, Dung LE, et al: Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. J Clin Oncol. 34 Suppl 15:S60122016. | |
|
ClinicalTrials.gov, . NCT02358031 a study of pembrolizumab (MK-3475) for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck (MK-3475-048/KEYNOTE-048). https://clinicaltrials.gov/ct2/show/NCT02358031Jun. 2016 | |
|
Ferris RL, Blumenschein GR, Fayette J, Guigay J, Colevas D, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. J Clin Oncol. 34 Suppl 15:S60092016. | |
|
Ferris RL, Blumenschein GR, Fayette J, Guigay J, Colevas D, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for recurrent Squamous-cell carcinoma of the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Seki T, Yun J and Oh SP: Arterial endothelium-specifıc activin receptor-likekinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res. 93:682–689. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cunha SI and Pietras K: ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 117:6999–7006. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Clinical Trials.gov, . NCT01458392 Study of Dalantercept in Patients with squamous cell carcinoma of the head and neck. https://clinicaltrials.gov/ct2/show/NCT01458392Jun. 2016 | |
|
Hawinkels LJ, de Vinuesa AG, Paauwe M, Kruithof-de Julio M, Wiercinska E, Pardali E, Mezzanotte L, Keereweer S, Braumuller TM, Heijkants RC, et al: Activin Receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. Clin Cancer Res. 22:96–106. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, Kratzke RA, Greeno EW and Kumar P: Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer. 100:1379–1384. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, et al: Nuclear factor-kappa B pathway and response in bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 21:864–870. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, et al: Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab and radiotherapy for head and neck cancer. Clin Cancer Res. 17:5755–5764. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 333:1154–1157. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, et al: Activation of the NOTCH pathway in Head and Neck cancer. Cancer Res. 74:1091–1104. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Platonova N, Lesma E, Basile A, Bignotto M, Garavelli S, Palano MT, Moschini A, Neri A, Colombo M and Chiaramonte R: Targeting Notch as a therapeutic approach for human malignancies. Curr Pharm Des. 23:108–134. 2017.PubMed/NCBI | |
|
Platonova N, Parravicini C, Sensi C, Paoli A, Colombo M, Neri A, Eberini I and Chiaramonte R: Identification of small molecules uncoupling the Notch: Jagged interaction through an integrated high-throughput screening. PLoS One. 12:e01826402017. View Article : Google Scholar : PubMed/NCBI |
